The Association for Frontotemporal Degeneration

FTD is caused by
degeneration of the frontal
and/or temporal lobes of the brain.

It's the most common form of dementia for people under 60.

What is FTD?

Learn More

Download a Diagnostic Checklist

You don't have to take
this journey alone.

AFTD offers reliable information, resources,
and support for families facing FTD.

Find Support Managing FTD Newly Diagnosed

Bruce Willis & FTD

The Willis' Unexpected Journey

Initial Family Statement

Read about Emma Heming Willis' book tour

Learn more about FTD

AFTD CEO
Susan Dickinson to Retire in May 2026

Read More View Job Posting

AFTD Board Leading Search for Successor

Supporting FTD Care Partners with Individual Therapy:

HEALTHCARE PROFESSIONAL WEBINAR

Approaches and Key Considerations

CEC credit available for viewing the live webinar

Tuesday, November 18, 2025
12-1 p.m. EST

Read the Full Plan

2025-2028

Paving the Path Forward:

Strategic Plan

Diagnosis and Treatment

Quality Care and Support

Advocacy and Awareness

Infrastructure and Sustainability

Since research is expanding so rapidly, AFTD is pleased to offer two ways for you to stay informed based on your level of scientific understanding.

Are you interested in staying up to date on FTD research?

Written for People on the FTD Journey Written for Researchers & Professionals

News & Events

Alector Therapeutics Announced Results from their Phase 3 Clinical Trial evaluating Latozinemab

Alector Therapeutics announced results from their Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) for people with FTD caused by variants in the progranulin (GRN gene). See Alector’s press release…

New York State FTD Registry Bill Signed into Law

KING OF PRUSSIA, Pa., Oct. 20, 2025 — New York State Governor Kathy Hochul on Friday signed into law a bill creating the nation’s first state-level frontotemporal dementia (FTD) registry. The New…

Advancing Hope: AFTD Convenes 3rd Annual FTD Research Roundtable Meeting

AFTD’s 2025 FTD Research Roundtable, in-person meeting, was held September 15-17 in Arlington, Virginia. Approximately 100 scientific stakeholders from academia, the biopharmaceutical industry, government & regulatory representatives, nonprofit partners, persons…

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

News & Events

Alector Therapeutics Announced Results from their Phase 3 Clinical Trial evaluating Latozinemab

New York State FTD Registry Bill Signed into Law

Advancing Hope: AFTD Convenes 3rd Annual FTD Research Roundtable Meeting

Epilepsy More Common in FTD than Alzheimer’s, Study Finds

Advancing Hope – AFTD Staff Attend 2025 ALS Nexus in Dallas

The Lived Experience of FTD: The Benefits of Pets

Dr. Laura Podcast Hosts AFTD’s Esther Kane

Advancing Hope: AFTD Helps Organize C9orf72 Prevention Trial Workshop

Have Questions?